In a wide-ranging interview featured in the latest edition of HealthInvestor (February 2019), our chairman Robert Barr discusses Creavo’s MCG device Corsens, and shares our ambitious plans for commercialisation and the potential for further device applications.

Robert describes Creavo’s fascinating history and how, having seen an early prototype of an MCG device built by our Chief Scientific Officer Ben Varcoe, he spotted the potential for the technology to solve an unmet need in healthcare.

Discussing the commercial potential for the device, Robert said in the article: “We estimate there’s a $4 billion market because this is not just an issue here in the UK, but exists across Europe, the East and North America, too”

Read the full feature here: